Please assess the completion status of the following clinical trial:

Trial Title: Effect of Electroacupuncture Versus PFMT Plus Solifenacin for Mixed Urinary Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* females meet the meet the diagnostic criteria of mixed urinary incontinence~* aged 35-75 years~* moderate and severe urinary incontinence with the urinary incontinence severity index between 3 and 9~* suffering from urinary incontinence at least for 3 months with the 72-h incontinence episode frequency≥2 in the baseline assessment~* voluntarily join the research and sign the informed consent~Exclusion Criteria:~* pure stress urinary incontinence, pure urgency urinary incontinence, overflow incontinence and neurogenic bladder~* medicine use for urinary incontinence or may affect the bladder function, or taking any non-drug therapy (such as electric stimulation, bladder training and pelvic floor muscle training) in the last month~* symptomatic urinary tract infection and non-functional urologic disease~* having ever undergone an operation for urinary incontinence or on the pelvic floor (including hysterectomy)~* pelvic organ prolapse degree ≥2~* residual urinary volume (RUV) \>30 mL~* maximum flow rate (Qmax) \<20 mL/s;~* be allergic to solifenacin or having contradictions for muscarine antagonist (such as urinary retention, gastric retention, myasthenia gravis, ulcerative colitis and angle closure glaucoma)~* diseases affect function of lower urinary tract, such as uncontrolled diabetes, multiple sclerosis, Alzheimer's disease, Parkinson's disease, spinal injury, cauda equina injury and multiple system atrophy.~* serious cardiovascular, pulmonary, cerebral, liver, kidney, hematopoietic system or psychiatric disease and cognitive impairment~* patients with severe renal dysfunction or moderate hepatic dysfunction who are using strong Cyp3a4 Inhibitor like ketoconazole~* unable or limited to walking, up and down stairs and running~* poor compliance with electroacupuncture, pelvic floor muscle training or drug~* pregnancy, lactation or within the 12 months after birth~* having a cardiac pacemaker, a metal allergy, or a severe needle phobia.~* volunteer of other trials

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- acupuncture (Type: EXPERIMENTAL): BL33 and BL35 of both sides are used. Every session will last for 30 minuets and will be given every other day. There are 36 sessions for each participant in all (3 session per week, 12 weeks).
- Solifenacin plus PFMT (Type: ACTIVE_COMPARATOR): Both PFMT and solifenacin will be given for 36 weeks. Solifenacin will be taken 5mg once daily, before or after meal. PFMT includes intensive exercises conducted in hospital and home exercises. Intensive exercises will be done once every week for the first 12 weeks and once every four weeks for the 13th to 36th week. Home exercises will be done three times daily for 36 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).